• Home
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Investors
  • Aspergillosis
  • PC945
  • News
  • Contact
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole

Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announces it has raised $52 million in […]

06 December 2022

Read more

Pulmocide Receives Investment from the Cystic Fibrosis Foundation

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients at risk of developing serious complications associated with aspergillosis, today […]

21 December 2021

Read more

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients with invasive pulmonary aspergillosis who have failed prior therapy. Pulmocide […]

16 September 2021

Read more

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

– Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million […]

27 May 2021

Read more

Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections

London, UK, 11 March 2021 – Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific […]

11 March 2021

Read more

Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was […]

26 October 2020

Read more

Pulmocide announces four presentations on PC945 at the 9th Advances Against Aspergillosis and Mucormycosis conference in Lugano, Switzerland, 27 February – 1 March, 2020

London, UK, 2 March 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that company scientists gave 4 […]

02 March 2020

Read more

Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence

London, UK, 13 August 2019 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, is pleased to announce that in vitro data published […]

13 August 2019

Read more

Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus

Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of invasive fungal lung infections, announces the publication of data demonstrating the synergistic antifungal effect of combining topical administration […]

02 July 2019

Read more

Pulmocide at the upcoming Respiratory Innovation Summit in Dallas on May 17

We are honoured to have been selected to tell our story at the upcoming Respiratory Innovation Summit on May 17! RIS Agenda Pulmocide’s CSO, Dr. Pete Strong will be presenting […]

26 April 2019

Read more

  • ← Previous
  • 1
  • 2
  • 3
  • Next →

Categories

  • Company news
  • Events
  • Presentations And Publications
  • Product news
  • Uncategorised

Company Contact

Pulmocide Ltd
44 Southampton Buildings
London
WC2A 1AP

Tel: +44 203 763 9484
Email: admin@pulmocide.com

Visit Us
  • Sitemap
  • Cookie policy
© 2023 Pulmocide
Company Reg: 06182024   265 Strand London WC2R 1BH
Web Design Agency - Brandcast Media
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkCookies